Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.
Shen J, Yan J, Du J, Li X, Wei J, Liu Q, Yong H, Wang X, Chang X, Ding Z, Sun W, Liu C, Zhu S, Guo J, Li H, Liu Y, Zhang W, Liu Z, Li R, Liu B.
Shen J, et al. Among authors: chang x.
Front Immunol. 2023 Mar 28;14:1133689. doi: 10.3389/fimmu.2023.1133689. eCollection 2023.
Front Immunol. 2023.
PMID: 37056765
Free PMC article.
Clinical Trial.